{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:06:03Z","timestamp":1780409163379,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.contraception.2023.110309","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T10:51:59Z","timestamp":1697280719000},"page":"110309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Characteristics and hormonal contraception use patterns of levonorgestrel 13.5\u00a0mg intrauterine device users in Sweden 2014\u20132016"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-2189","authenticated-orcid":false,"given":"Marie","family":"Linder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Schoendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Schulze-Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn E.","family":"Cesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2023.110309_bib1","unstructured":"Jaydess: Summary of Product Characteristics (2022-09\u201305). Available from: \u3008https:\/\/www.medicines.org.uk\/emc\/product\/5297\/smpc#gref\u3009."},{"issue":"3","key":"10.1016\/j.contraception.2023.110309_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jfprhc-2012-100392","article-title":"Uptake and continuation rates of the intrauterine system in a university student general practice population in the UK","volume":"39","author":"Armitage","year":"2013","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2023.110309_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/ejc.6.s1.23.26","article-title":"Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland","volume":"6","author":"Backman","year":"2001","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"11","key":"10.1016\/j.contraception.2023.110309_bib4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1600-0412.2011.01256.x","article-title":"Recent developments in the clinical use of the levonorgestrel-releasing intrauterine system","volume":"90","author":"Gemzell-Danielsson","year":"2011","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"10.1016\/j.contraception.2023.110309_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jfprhc-2014-101046","article-title":"Intrauterine contraception in nulliparous women: a prospective survey","volume":"42","author":"Hall","year":"2016","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"4","key":"10.1016\/j.contraception.2023.110309_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.contraception.2016.11.005","article-title":"A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population","volume":"95","author":"Fan","year":"2017","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2023.110309_bib7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.contraception.2016.02.004","article-title":"A phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents","volume":"93","author":"Gemzell-Danielsson","year":"2016","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.contraception.2023.110309_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/13625187.2016.1212987","article-title":"A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age","volume":"21","author":"Borgatta","year":"2016","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"9","key":"10.1016\/j.contraception.2023.110309_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135309","article-title":"The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine contraceptive systems: subgroup analyses of data from a phase III trial","volume":"10","author":"Gemzell-Danielsson","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.contraception.2023.110309_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.fertnstert.2016.02.036","article-title":"A 12- month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant","volume":"106","author":"Apter","year":"2016","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.contraception.2023.110309_bib11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/09513590.2017.1416465","article-title":"Long-acting reversible contraception (LARC) with the intrauterine system with levonorgestrel (6 mcg\/d): observational study on the acceptability, quality of life, and sexuality in Italian women","volume":"34","author":"Neri","year":"2018","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.contraception.2023.110309_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/13625187.2018.1433824","article-title":"Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy","volume":"23","author":"Caruso","year":"2018","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2023.110309_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/jfprhc-2014-100980","article-title":"Jaydess\u00ae levonorgestrel intrauterine system","volume":"40","author":"Melvin","year":"2014","journal-title":"Fam Plann Reprod Health Care"},{"issue":"6","key":"10.1016\/j.contraception.2023.110309_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.contraception.2016.08.011","article-title":"Use of intrauterine devices in nulliparous women","volume":"95","author":"Lohr","year":"2017","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2023.110309_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/13625187.2020.1843015","article-title":"Predicting menstrual bleeding patterns with levonorgestrel-releasing intrauterine systems","volume":"26","author":"Frenz","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"11","key":"10.1016\/j.contraception.2023.110309_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"10.1016\/j.contraception.2023.110309_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/GME.0000000000000261","article-title":"Relationship between age at natural menopause and risk of heart failure","volume":"22","author":"Rahman","year":"2015","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.contraception.2023.110309_bib18","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.3892\/ol.2016.4390","article-title":"Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment","volume":"11","author":"Macchia","year":"2016","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.contraception.2023.110309_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.6118\/jmm.20000","article-title":"The 2020 Menopausal Hormone Therapy Guidelines","volume":"26","author":"Lee","year":"2020","journal-title":"J Menopausal Med"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423004158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423004158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:23:54Z","timestamp":1757881434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782423004158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":19,"alternative-id":["S0010782423004158"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2023.110309","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and hormonal contraception use patterns of levonorgestrel 13.5\u00a0mg intrauterine device users in Sweden 2014\u20132016","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2023.110309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110309"}}